Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews

Ref ID	1038
First Author	M. Mainou
Journal	ANNALS OF HEMATOLOGY
Year Of Publishing	2024
URL	https://link.springer.com/article/10.1007/s00277-023-05517-7
Keywords	• Harms • Oncology • Low methodological quality • Disclosure • Protocols • Haematology
Problem(s)	• No registered or published protocol • Low methodological (AMSTAR) quality • Conflicts of interest or funding of included studies not assessed • Reasons for excluding potentially eligible studies not provided • Meta-analyses and forest plots presented without considering risk of bias / quality
Number of systematic reviews included	23
Summary of Findings	From 23 included 7 SRs indexed on Medline, Cochrane Library, Epistemonikos.org up to September 2023, focusing on adverse events due to antimyeloma treatments. The quality of included studies as judged by AMSTAR 2 was mostly critically low. None of the reviews provided a list of excluded studies, or reported on the sources of funding of studies, only 1 review assessed the potential impact of risk of bias in individual studies on the results of the meta-analysis, and 9 reviews (39.1%) did not have an a priori registered protocol.
Did the article find that the problem(s) led to qualitative changes in interpretation of the results?	N/A
Are the methods of the article described in enough detail to replicate the study?